Phase 2 Apecotrep Delivers 40% Proteinuria Reduction in FSGS
Apecotrep is an investigational oral small-molecule TRPC5 channel inhibitor being developed for focal segmental glomerulosclerosis (FSGS); early reports describe a clinically meaningful reduction in proteinuria in a phase 2 setting, consistent with the established role of the TRPC5–Rac1 pathway in driving podocyte injury and proteinuria.
Background
FSGS is a podocytopathy and a leading glomerular cause of kidney failure, with limited effective therapies. The transient receptor potential canonical-5 (TRPC5) channel regulates calcium signaling and cytoskeletal dynamics in podocytes, and overactivation of the TRPC5–Rac1 pathway has been implicated in podocyte injury and proteinuria; in animal models, small-molecule TRPC5 inhibitors suppressed proteinuria and prevented podocyte loss, providing the rationale for podocyte-targeted TRPC5 inhibitors such as apecotrep.
Key findings
This phase 2 report describes a reduction in proteinuria with apecotrep in patients with FSGS. The precise magnitude, comparator, sample size, and statistical results were not available in the peer-reviewed literature retrieved for this summary, so the headline figure should be interpreted as a preliminary, study-reported result pending full publication. The direction of effect — proteinuria lowering via TRPC5 blockade — aligns with prior preclinical evidence and with the broader class of podocyte-targeted channel inhibitors being studied in FSGS.
Clinical implications
Proteinuria reduction is a recognized surrogate endpoint in FSGS trials, and a positive phase 2 proteinuria signal would support advancing apecotrep into larger, longer controlled trials powered for kidney-function outcomes. As with other early-phase FSGS agents, durability of benefit, effect on eGFR slope, and performance across primary versus genetic FSGS subgroups remain to be established before any change in clinical practice.
Category
Research
Source
The Lancet
More from ASNRT News
Browse the latest news, society announcements, KDIGO guideline updates, and AJNT issue releases on the ASNRT newsroom.